DTIL — Precision BioSciences Inc
NASDAQ · Healthcare · Biotechnology
$7.77
+$0.13 (+1.70%)
Precision BioSciences Inc (DTIL) is a biotechnology company listed on NASDAQ. It is led by Michael Amoroso, based in 302 East Pettigrew St., Durham, NC, United States, 27701, with about 107 employees. Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Latest reported DTIL revenue for 2025-09-30 was $13.0K. Net income was -$65.9M. Revenue was down 27.8% from 2025-06-30 to 2025-09-30. DTIL currently screens at market cap $48.1M.
Use this DTIL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DTIL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DTIL SEC filings page. Lician reads the product cache first so this HTML stays unique to Precision BioSciences Inc even when a live quote feed is slow.
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL Key Statistics
Market Cap
$48.12M
Volume
232,699
Previous Close
$8.85
Day Range
$8.36 – $8.82
EPS
$1.04
Revenue
$68.70M
Net Income
$7.17M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+41.0%
Profit Margin
10.4%
Employees
107
DTIL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $68.70M | $48.73M | $25.10M | $115.53M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $7.17M | -$61.32M | -$111.64M | -$30.60M |
| EPS (Diluted) | $1.04 | -$15.96 | -$38.10 | -$0.52 |
Total Assets
$136.39M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$85.90M
Operating Cash Flow
-$58.45M
Free Cash Flow
$0.00
Precision BioSciences Inc Company Information
- President, CEO & Director
- Michael Amoroso
- Headquarters
- 302 East Pettigrew St., Durham, NC, United States, 27701
- Website
- precisionbiosciences.com
- Phone
- 919 314 5512
- IPO / Founded
- 2019-03-28
- Sector
- Healthcare
- Industry
- Biotechnology